The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...